Navigation Links
Marshall Edwards to Host Annual Meeting of Stockholders
Date:3/10/2011

SAN DIEGO, March 10, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it will host its Annual Meeting of Stockholders on Wednesday, April 13, 2011 at 10:00 a.m. at the offices of Morgan, Lewis & Bockius LLP, located at 101 Park Avenue, New York, New York 10178, to consider and vote on certain matters, including the approval of the transactions contemplated by the asset purchase agreement, dated December 21, 2010, between the Company and Novogen Limited, the election of directors, the adoption of advisory resolutions relating to executive compensation, and the ratification of the appointment of the Company's independent registered public accounting firm for the year ending June 30, 2011. In addition, Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on the Company and its lead oncology programs. A live webcast of the meeting will be accessible at www.marshalledwardsinc.com.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes Phenoxodiol and its next-generation drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Important Information for Investors and Stockholders

This release does not constitute an offer to sell or the solicitation of an offer to buy securities or a solicitation of any vote or approval. In connection with the proposed asset purchase transaction, the Company has filed with the U.S. Securities and Exchange Commission (the "SEC"), and the SEC has declared effective as of March 7, 2011, a registration statement on Form S-4 that contains preliminary proxy statements of the Company and Novogen, as well as a preliminary prospectus of the Company. The Company and Novogen may also file other documents with the SEC regarding the proposed transaction. BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION, STOCKHOLDERS OF THE COMPANY AND NOVOGEN ARE URGED TO READ THEM CAREFULLY, IF AND WHEN THEY BECOME AVAILABLE. The registration statement is, and the prospectus and related materials will be, available free of charge (along with any other documents and reports filed by the Company or Novogen with the SEC) at the SEC's website, www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company's internet website at www.marshalledwardsinc.com or by contacting the Company's Investor Relations Department at 858-792-3729 or by email atpete.despain@marshalledwardsinc.com. Copies of the documents filed with the SEC byNovogen will be available free of charge on Novogen's internet website at www.novogen.com.

The Company, Novogen and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Novogen and the Company in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction has been included in the registration statement and will also be included in the prospectus described above. Additional information regarding the directors and executive officers of the Company is included in the Company's Annual Report on Form 10-K/A for the year ended June 30, 2010, which was filed with the SEC on October 28, 2010 and is available free of charge at the SEC's website, www.sec.gov. Additional information regarding the directors and executive officers of Novogen is included in Novogen's Annual Report on Form 20-F for the year ended June 30, 2010, which was filed with the SEC on December 13, 2010 and is available free of charge at the SEC's website, www.sec.gov. Stockholders may obtain additional information regarding the proposed transaction by reading the joint proxy statement/prospectus described above and the related materials relating to the proposed transaction, if and when they become available.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
2. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
3. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
4. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
5. Cantel Medical Corp. to Present at The Sidoti & Company LLC Fifteenth Annual Emerging Growth Institutional Investor Forum
6. Trinity Biotech plc to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference
7. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
8. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
9. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
10. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
11. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):